Literature DB >> 16188964

Intratypic recombination among lineages of type 1 vaccine-derived poliovirus emerging during chronic infection of an immunodeficient patient.

Chen-Fu Yang1, Hour-Young Chen, Jaume Jorba, Hui-Chih Sun, Su-Ju Yang, Hsiang-Chi Lee, Yhu-Chering Huang, Tzou-Yien Lin, Pei-Jer Chen, Hiroyuki Shimizu, Yorihiro Nishimura, Andi Utama, Mark Pallansch, Tatsuo Miyamura, Olen Kew, Jyh-Yuan Yang.   

Abstract

We determined the complete genomic sequences of nine type 1 immunodeficient vaccine-derived poliovirus (iVDPV) isolates obtained over a 337-day period from a poliomyelitis patient from Taiwan with common variable immunodeficiency. The iVDPV isolates differed from the Sabin type 1 oral poliovirus vaccine (OPV) strain at 1.84% to 3.15% of total open reading frame positions and had diverged into at least five distinct lineages. Phylogenetic analysis suggested that the chronic infection was initiated by the fifth and last OPV dose, given 567 days before onset of paralysis, and that divergence of major lineages began very early in the chronic infection. Key determinants of attenuation in Sabin 1 had reverted in the iVDPV isolates, and representative isolates of each lineage showed increased neurovirulence for PVR-Tg21 transgenic mice. None of the isolates had retained the temperature-sensitive phenotype of Sabin 1. All isolates were antigenic variants of Sabin 1, having multiple amino acid substitutions within or near neutralizing antigenic sites 1, 2, and 3a. Antigenic divergence of the iVDPV variants from Sabin 1 followed two major independent evolutionary pathways. The emergence of distinct coreplicating lineages suggests that iVDPVs can replicate for many months at separate sites in the gastrointestinal tract. Some isolates had mosaic genome structures indicative of recombination across and within lineages. iVDPV excretion apparently ceased after 30 to 35 months of chronic infection. The appearance of a chronic VDPV excretor in a tropical, developing country has important implications for the strategy to stop OPV immunization after eradication of wild polioviruses.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16188964      PMCID: PMC1235840          DOI: 10.1128/JVI.79.20.12623-12634.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  78 in total

1.  Common variable immunodeficiency: clinical and immunological features of 248 patients.

Authors:  C Cunningham-Rundles; C Bodian
Journal:  Clin Immunol       Date:  1999-07       Impact factor: 3.969

Review 2.  Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: a review of the literature.

Authors:  J P Alexander; H E Gary; M A Pallansch
Journal:  J Infect Dis       Date:  1997-02       Impact factor: 5.226

3.  MODELTEST: testing the model of DNA substitution.

Authors:  D Posada; K A Crandall
Journal:  Bioinformatics       Date:  1998       Impact factor: 6.937

4.  Serotype-specific identification of polioviruses by PCR using primers containing mixed-base or deoxyinosine residues at positions of codon degeneracy.

Authors:  D R Kilpatrick; B Nottay; C F Yang; S J Yang; E Da Silva; S Peñaranda; M Pallansch; O Kew
Journal:  J Clin Microbiol       Date:  1998-02       Impact factor: 5.948

5.  Group-specific identification of polioviruses by PCR using primers containing mixed-base or deoxyinosine residue at positions of codon degeneracy.

Authors:  D R Kilpatrick; B Nottay; C F Yang; S J Yang; M N Mulders; B P Holloway; M A Pallansch; O M Kew
Journal:  J Clin Microbiol       Date:  1996-12       Impact factor: 5.948

6.  Comparative study of five methods for intratypic differentiation of polioviruses.

Authors:  H G van der Avoort; B P Hull; T Hovi; M A Pallansch; O M Kew; R Crainic; D J Wood; M N Mulders; A M van Loon
Journal:  J Clin Microbiol       Date:  1995-10       Impact factor: 5.948

7.  PAML: a program package for phylogenetic analysis by maximum likelihood.

Authors:  Z Yang
Journal:  Comput Appl Biosci       Date:  1997-10

8.  Genetic basis of the neurovirulence of type 1 polioviruses isolated from vaccine-associated paralytic patients.

Authors:  J Li; L B Zhang; T Yoneyama; H Yoshida; H Shimizu; K Yoshii; M Hara; T Nomura; H Yoshikura; T Miyamura; A Hagiwara
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

9.  Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient.

Authors:  O M Kew; R W Sutter; B K Nottay; M J McDonough; D R Prevots; L Quick; M A Pallansch
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

10.  Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination.

Authors:  K S Lole; R C Bollinger; R S Paranjape; D Gadkari; S S Kulkarni; N G Novak; R Ingersoll; H W Sheppard; S C Ray
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

View more
  32 in total

1.  Detection of unusual mutation within the VP1 region of different re-isolates of poliovirus Sabin vaccine.

Authors:  Evaggelos Dedepsidis; Ioannis Karakasiliotis; Eleni Paximadi; Zaharoula Kyriakopoulou; Dimitrios Komiotis; Panayotis Markoulatos
Journal:  Virus Genes       Date:  2006-10       Impact factor: 2.332

2.  Modulation of poliovirus replicative fitness in HeLa cells by deoptimization of synonymous codon usage in the capsid region.

Authors:  Cara Carthel Burns; Jing Shaw; Ray Campagnoli; Jaume Jorba; Annelet Vincent; Jacqueline Quay; Olen Kew
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

3.  Calibration of multiple poliovirus molecular clocks covering an extended evolutionary range.

Authors:  Jaume Jorba; Ray Campagnoli; Lina De; Olen Kew
Journal:  J Virol       Date:  2008-02-20       Impact factor: 5.103

4.  Evolution of the Sabin vaccine into pathogenic derivatives without appreciable changes in antigenic properties: need for improvement of current poliovirus surveillance.

Authors:  Maria L Yakovenko; Ekaterina A Korotkova; Olga E Ivanova; Tatyana P Eremeeva; Elena Samoilovich; Iryna Uhova; Gene V Gavrilin; Vadim I Agol
Journal:  J Virol       Date:  2009-01-07       Impact factor: 5.103

5.  Highly divergent type 2 and 3 vaccine-derived polioviruses isolated from sewage in Tallinn, Estonia.

Authors:  Haider Al-Hello; Jaume Jorba; Soile Blomqvist; Riina Raud; Olen Kew; Merja Roivainen
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

6.  Sabin and wild type polioviruses from children who presented with acute flaccid paralysis in Nigeria.

Authors:  A O Adedeji; I O Okonko; F D Adu
Journal:  Afr Health Sci       Date:  2012-09       Impact factor: 0.927

7.  Identification of vaccine-derived polioviruses using dual-stage real-time RT-PCR.

Authors:  David R Kilpatrick; Karen Ching; Jane Iber; Qi Chen; Su-Ju Yang; Lina De; A J Williams; Mark Mandelbaum; Hong Sun; M Steven Oberste; Olen M Kew
Journal:  J Virol Methods       Date:  2013-12-07       Impact factor: 2.014

Review 8.  New generation of inactivated poliovirus vaccines for universal immunization after eradication of poliomyelitis.

Authors:  Konstantin Chumakov; Ellie Ehrenfeld
Journal:  Clin Infect Dis       Date:  2008-12-15       Impact factor: 9.079

9.  New vaccine design based on defective genomes that combines features of attenuated and inactivated vaccines.

Authors:  Teresa Rodríguez-Calvo; Samuel Ojosnegros; Marta Sanz-Ramos; Juan García-Arriaza; Cristina Escarmís; Esteban Domingo; Noemí Sevilla
Journal:  PLoS One       Date:  2010-04-29       Impact factor: 3.240

10.  Codon usage determines the mutational robustness, evolutionary capacity, and virulence of an RNA virus.

Authors:  Adam S Lauring; Ashley Acevedo; Samantha B Cooper; Raul Andino
Journal:  Cell Host Microbe       Date:  2012-11-15       Impact factor: 21.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.